Anogenital Distance Differences Between Transgender Males and Female Individuals
1 other identifier
observational
150
1 country
1
Brief Summary
This study evaluates the anogenital distance measurement differences between transgender male individuals and normal healthy female individuals. Half of the participants will be selected from the men with a masculine gender identity who were assigned female sex at birth (Woman who wanted to be a man). Transgender men will be evaluated with the vaginal examination, and anogenital distance will be measured at the time of gynecological medico-legal evaluation before the sex reassignment surgery. While the other half of the participants will be selected from healthy female individuals, ordinary healthy women will be selected from patients who come to the gynecology clinic for another reason (Women with normal sexual orientation).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 26, 2018
CompletedFirst Posted
Study publicly available on registry
December 28, 2018
CompletedStudy Start
First participant enrolled
April 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 15, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 15, 2020
CompletedApril 2, 2019
March 1, 2019
11 months
December 26, 2018
March 31, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Anogenital Distance (Anus-Clitoris)
Anogenital Distance (Anus-Clitoris) will be measured from the anterior clitoral surface to the centre of the anus with a digital caliper in centimeters.
1 hour
Anogenital Distance (Anus-Posterior Fourchette)
Anogenital Distance (Anus-Posterior Fourchette) will be measured from the posterior fourchette to the centre of the anus with a digital caliper in centimeters.
1 hour
Secondary Outcomes (2)
Anti-Mullerian Hormone (AMH) level measurement
8 hours
FSH (Follicle-stimulating hormone), LH (Luteinizing hormone), Estradiol, and Testosteron level measurements
8 hours
Study Arms (2)
Transgender Male individuals
* Group Description: This group consists of transgender male individuals who come to the gynecology clinic for medico-legal evaluation before the sex reassignment surgery. * Intervention: Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position.
Normal healthy female individuals
* Group Description: Healthy women with normal sexual orientation. * Intervention: (The same) Anogenital distance measurement with a digital caliper in centimeters in the lithotomy position.
Interventions
The women were kindly asked to lay down in the lithotomy position with their thighs at 45° to the examination table. A digital caliper (Mitutoyo 500-752-10 ABSOLUTE Digimatic Coolant Proof Caliper 0-150mm / 0-6", Mitutoyo Corporation, Japan) was used to measure anogenital distance. Anogenital distance anus to clitoris: will be measured in centimeters from the anterior clitoral surface to the center of the anus. Anogenital distance anus to fourchette: will be measured in centimeters from the posterior fourchette to the center of the anus. Two investigators who were blind to the gynecological status of the women will measure each distance three times, and the mean value of the six measurements of each anogenital distance will be used.
Eligibility Criteria
The study population will be healthy transgender male individuals whose gender identity (Male) are different from their birth-assigned sex (Female). These individuals are healthy biologically female persons and want to change their gender to male status. In Turkey, if a woman wants to change her gender, she has to bring a lawsuit against the birth registration office to change her gender to male status. Medico-legal assessments then have to be made at a tertiary gynecological center through the court. The participants will be invited to the study at the time of medico-legal evaluation before the sex reassignment surgery.
You may qualify if:
- Individuals who are 18-50 years old.
- Healthy transgender male individuals whose gender identity (Male) are different from their birth-assigned sex (Female). The participants will be invited to the study at the time of medico-legal evaluation before the sex reassignment surgery.
You may not qualify if:
- Individuals who are older than 50 (People older than 50 cannot change their gender legally in Turkey).
- Other sexual orientation disorders. (Lesbian, Gay, Bisexual, Queer, Intersex, or Asexual persons)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Uludag University Hospital, Department of Obstetrics and Gynecology
Bursa, Ozluce, 16059, Turkey (Türkiye)
Related Publications (2)
Wu Y, Zhong G, Chen S, Zheng C, Liao D, Xie M. Polycystic ovary syndrome is associated with anogenital distance, a marker of prenatal androgen exposure. Hum Reprod. 2017 Apr 1;32(4):937-943. doi: 10.1093/humrep/dex042.
PMID: 28333243BACKGROUNDSanchez-Ferrer ML, Mendiola J, Hernandez-Penalver AI, Corbalan-Biyang S, Carmona-Barnosi A, Prieto-Sanchez MT, Nieto A, Torres-Cantero AM. Presence of polycystic ovary syndrome is associated with longer anogenital distance in adult Mediterranean women. Hum Reprod. 2017 Nov 1;32(11):2315-2323. doi: 10.1093/humrep/dex274.
PMID: 29025054BACKGROUND
Study Officials
- STUDY DIRECTOR
Adnan Orhan, M.D.
Uludag University, Department of Obstetrics and Gynecology
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Obstetrician and Gynecologist (M.D. and researcher)
Study Record Dates
First Submitted
December 26, 2018
First Posted
December 28, 2018
Study Start
April 1, 2019
Primary Completion
February 15, 2020
Study Completion
March 15, 2020
Last Updated
April 2, 2019
Record last verified: 2019-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ICF
- Time Frame
- Data will be available within 9 months of study completion.
- Access Criteria
- Data access requests will be reviewed by an external independent review panel. Requestors will be required to sign a data access agreement.
De-identified individual participant data for all primary and secondary outcome measures will be made available.